Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 37,800 shares, a decrease of 49.5% from the March 31st total of 74,800 shares. Based on an average daily trading volume, of 770,200 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the company are short sold.

Institutional Trading of Achilles Therapeutics

An institutional investor recently bought a new position in Achilles Therapeutics stock. Vestal Point Capital LP purchased a new position in Achilles Therapeutics plc (NASDAQ:ACHL) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 108,083 shares of the company’s stock, valued at approximately $96,000. Vestal Point Capital LP owned 0.27% of Achilles Therapeutics at the end of the most recent quarter. 56.38% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ACHL has been the subject of a number of analyst reports. Chardan Capital reduced their target price on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, April 5th. Piper Sandler reissued a “neutral” rating and set a $2.00 target price (down from $8.00) on shares of Achilles Therapeutics in a research note on Friday, April 5th.

Achilles Therapeutics Stock Down 1.9 %

Achilles Therapeutics stock opened at $0.76 on Friday. The firm has a 50-day moving average price of $1.11 and a two-hundred day moving average price of $0.96. The firm has a market capitalization of $30.31 million, a price-to-earnings ratio of -0.44 and a beta of 1.09. Achilles Therapeutics has a 52-week low of $0.74 and a 52-week high of $1.76.

Achilles Therapeutics (NASDAQ:ACHL) last posted its earnings results on Thursday, April 4th. The company reported ($0.46) earnings per share (EPS) for the quarter. Research analysts expect that Achilles Therapeutics will post -1.34 earnings per share for the current year.

Achilles Therapeutics Company Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.